Investors
News
Subscribe
Hit enter to search or ESC to close
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Cardiovascular Disease
Metabolic Disease
Liver Disease
Arthritis
Aging
Coronavirus Disease 2019 (COVID-19)
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact Us
Press Releases
Investor Relations
Investors
Overview
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
Company Info
Profile
Management Team
Contacts
FAQ
Financial Info
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
All News
2023
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2007
2006
Cardax Reports 2017 Results
Mar 27, 2018
Cardax Inks Deal to Distribute ZanthoSyn® in China
Feb 17, 2018
Cardax's ZanthoSyn® is No. 1 Seller at GNC Hawaii Stores
Feb 17, 2018
Cardax Hires Gilbert Shin as VP, Retail Sales and Marketing
Dec 7, 2017
ZanthoSyn® from Cardax Now Available at 3,000+ GNC Corporate Stores in the U.S.
Dec 7, 2017
Cardax Refutes Allegations by Competitive Trade Group, NAXA
Dec 5, 2017
Cardax Reports Q3 2017 Results
Nov 14, 2017
Cardax to Lead Plenary Session at Regenerative Medicine Conference
Nov 6, 2017
Cardax and GNC Sign Mutual Exclusivity Agreement for ZanthoSyn®
Oct 20, 2017
Cardax Welcomes Cardiovascular Research Breakthrough
Sep 19, 2017
1
2
3
4
5
6
7
8
9
News / Events
Press Releases
Media Coverage
IR Calendar
Presentations
Email Alerts
About Us
Corporate Overview
Management Team
Board of Directors
Scientific Advisory Board
Company History
Astaxanthin
Overview
Astaxanthin Overview
History and Background
Safety
Mechanism of Action
Synthetic vs. Natural Astaxanthin
Research in Key Addressable Markets
Scientific Literature
Programs
Product Platform
Commercialization Strategy
ZanthoSyn
®
CDX-101
CDX-301
CHASE Clinical Trial
Intellectual Property
Newsroom
Investors
Investor Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Contact Us
Investors
News
Subscribe
